Share
 
Title
Code
Session Type
Channel
Date Time
Chair:

This session will review the efficacy data from the two latest clinical trials recently completed, namely the HPTN 084 (Life) and the Antibody Mediated Prevention (AMP) trials. This will be followed by a moderated panel discussion to review the implications for prevention and for HIV globally.

HY01.01LB VRC01 antibody prevention of HIV
Lawrence Corey, Fred Hutchinson Cancer Research Center, United States
Abstract
HY01.02LB Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084
Sinead DELANY-MORETLWE, WRHI, South Africa
Abstract

HY01.03 Panel discussion
Lawrence Corey, Fred Hutchinson Cancer Research Center, United States
Sinead DELANY-MORETLWE, WRHI, South Africa
Connie CELUM, University of Washington, United States
Jorge SANCHEZ, CITBM - Centro de Investigaciones Tecnológicas Biomédicas y Medioambientales, Peru
Nyaradzo MGODI, University of Zimbabwe College of Health Sciences, Zimbabwe
Raphael LANDOVITZ, UCLA Center for Clinical AIDS Research & Education, United States